Skip to main content

A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis



from Neurology : nature.com subject feeds https://ift.tt/MhAs8f9

Comments